ArticleBMC microbiology2026
Unveiling the antibacterial activity and mechanisms of BMS-303141 against Staphylococcus aureus.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The rising prevalence of multidrug-resistant (MDR) Staphylococcus aureus (S. aureus), particularly methicillin-resistant S. aureus (MRSA), poses ongoing clinical challenges, driving an urgent need for novel antibacterial agents. Here, we report the first identification of BMS-303141 (an ATP-citrate lyase inhibitor) as a potent anti-staphylococcal compound that induces multi-pathway cellular disruption. BMS-303141 exhibited potent antibacterial activity against MRSA, with the minimum inhibitory concentration (MIC) ranging from 6.25 to 12.5 μM (2.65-5.30 μg/mL) and inhibited biofilm formation at sub-MIC concentrations. Integrative proteomics and whole-genome sequencing revealed multi-pathway cellular disruption involving cell wall integrity and protein synthesis pathways, as indicated by differentially expressed proteins and mutated genes (Atl, LytH, Rot, OatA, Asd, ClfA, FnbA, SdrD, dltB). Mechanistic studies further demonstrated disruption of membrane phospholipid homeostasis and peptidoglycan homeostasis by BMS-303141. Critically, in mouse wound and thigh muscle infection models, BMS-303141 significantly reduced bacterial burden and accelerated healing, demonstrating therapeutic potential against S. aureus. Together, these findings indicate that BMS-303141 is a promising lead for developing new antibacterial agents against S. aureus and its resistant strains.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.